Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine dose-ranging PCIA study after VATS
ChiCTR2200058890Phase 4Completed
- Sponsor
- Department of Anesthesiology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University
- Start
- May 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine and hydromorphone in postoperative pain (4 arms), sponsored by Department of Anesthesiology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University. Primary endpoint: Proportion of patients experiencing moderate-to-severe pain within the first 48 hours after surgery. Started May 2022; status: completed.
02
Drugs
esketaminehydromorphone
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2200058890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058890.